Form 4: Altimmune Executive Raymond Jordt Reports Stock Transactions

Altimmune's Chief Business Officer, Raymond Jordt, reports the acquisition and disposal of company stock and stock options.

Summary

• Raymond Jordt, Chief Business Officer of Altimmune, Inc., reported transactions involving the company's stock on January 25, 2025 and January 27, 2025.
• On January 25, 2025, 14,600 restricted stock units (RSUs) vested, resulting in the acquisition of 14,600 shares of common stock.
• Also on January 25, 2025, 3,862 shares were disposed of to cover taxes associated with the vesting of the RSUs at a price of $6.98 per share.
• On January 27, 2025, Jordt was granted 183,600 stock options with an exercise price of $7 and 63,400 restricted stock units.
• Following these transactions, Jordt directly owns 32,288 shares of common stock, 183,600 stock options and 63,400 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are generally neutral to positive. The vesting of shares and grant of options suggest confidence in the company's future.

Positives

• The vesting of restricted stock units and the grant of stock options and additional restricted stock units indicate continued alignment of executive interests with the company's performance.
• The vesting schedule of the stock options and restricted stock units encourages long-term commitment from the executive.

Negatives

• The disposal of 3,862 shares to cover taxes associated with the vesting of RSUs resulted in a reduction of Jordt's direct shareholdings.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The vesting of the stock options and restricted stock units is contingent on the executive's continued service with the company.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but it does outline the vesting schedules for the granted stock options and restricted stock units.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard forms of executive compensation in the biotechnology industry, used to align management interests with shareholder value.
• The vesting schedules described are typical for such grants, with vesting periods designed to incentivize long-term performance and retention.
• Companies like Moderna, BioNTech, and Regeneron also use similar equity-based compensation structures for their executives.

Stakeholder Impact

• The transactions reported in this filing provide transparency to shareholders regarding executive stock ownership.
• The vesting schedules of the stock options and restricted stock units align executive interests with long-term shareholder value.

Key Dates

Keywords

Altimmune, stock options, restricted stock units, insider trading, Form 4, executive compensation, stock vesting, Raymond Jordt